Dish of the day

Joiners: 

No joiners today. 

Leavers: 

No leavers today. 

 

What’s cooking in the IPO kitchen?** 

Announced ITF 26 September: Mydecine Innovations Group, a biotech and life sciences company that is building an R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems, intends to join the Access Segment of the AQSE Growth Market. Admission expected on 10 October. 

 

MicroSalt, the developer of salt-producing technology designed to deliver full flavor with less sodium, announces the launch of an exempt public offer of Shares to retail investors for up to £2.5m via PrimaryBid as part of its spin out from AIM listed Tekcapital plc (TEK.L). The Company is looking to raise £10m - £15m on IPO and announced revenues of US$0.638m in 2022, its first year of retail sales of SaltMe Crisp brand and Microsalt salt shakers in US based supermarkets and through Amazon US. Admission to trading on AIM is expected to be 18 October.

 

Banquet Buffet*** 

ADM Energy* 0.5p  £1.8m (ADME.L) 

A natural resources investing company notes the announcement that PetroNor E&P Limited (OSE Ticker: PNOR) has acquired the 32% cost sharing interest and 24% profit share interest of New Age (Africa Global Energy), Ltd. (New Age) in OML 113. PetroNor acquired New Age's interest in OML 113 for an upfront consideration of USD 6m, with a contingent consideration of up to USD 20m based on future gas production volumes. ADM holds a 9.2% profit interest in the Aje field in OML 113, which covers an area of 835km2 offshore Nigeria. Aje has multiple oil, gas and gas condensate reservoirs in the Turonian, Cenomanian and Albian sandstones with five wells drilled to date. 

 

Aurrigo International 167.5p  £69.8m (AURR.L) 

A international provider of transport technology solutions has signed a formal Partnership agreement with International Airlines Group, S.A., for the deployment and demonstration of Aurrigo's autonomous aviation solutions within the UK. The Partnership is expected to follow with an evaluation and simulation phase to commence in October 2023 and then run for four months, followed by a demonstration phase and an initial deployment. The first project and deployment of Aurrigo's vehicles under the trial programme, which will be undertaken at a large UK airport, will be valued at £0.25m. 

 

BiVictriX Therapeutics 14p  £11.6m (BVX.L) 

An biotechnology company applying a differentiated approach to developing anti-cancer precision Antibody Drug Conjugates, announces that it has appointed Adrian Howd, PhD as combined Chief Financial Officer (CFO) and Chief Business Officer (CBO). Alex Hughes will be stepping down from his position as CFO on 13 October. Adrian joins BiVictriX with over 20 years of strategic financial and commercial experience in the biopharmaceutical industry, having held various financial roles, private and public executive management positions and board roles across the sector. 

 

Gooch & Housego  544p  £140.3m (GHH.L) 

The manufacturer of photonic components & systems announces a trading update for the second half of the financial year.  Revenues for the financial year have marginally exceeded market expectations and the engineering team in Ashford is fully utilised supporting customers new instrument development and qualification programmes. The Company announced the integration of GS Optics and Artemis into the G&H Group which is proceeding to plan. The Company mentions net debt at the financial year end is expected to be better than market expectations and theGroup’s order book stood at £124.9m at 30 September 2023. 

 

Inspiration Healthcare Group 42p  £28.7m (IHC.L) 

The medical technology company announces its unaudited interim results for the six months ended 31 July 2023. Revenue marginally decreased to £20.4m (H1 2023: £20.5m) however, gross margin improved to 48.6% (H1 2023 45.1%). Adjusted EBITDA was £1.8m (H1 2023: £2.2m) and operating profit £0.6m (H1 2023: £1.0m). The Company has net debt of £2.1m (31 January 2023: £3.8m) and the Company looks ahead with optimism. 

 

Pressure Technologies 27.5p  £10.6m (PRES.L) 

The specialist engineering group announces a business update for the financial year ended 30 September 2023 (FY23). Revenues were reported of c.£32m (FY22: £25m) in FY23, representing growth of 28%, as a result, expected adjusted EBITDA of c.£2.0m (FY22: loss of £0.9m). The Company has net debt of £2.4m (FY22: 3.5m) a reduction of 31% and Group order intake of £43m (FY22: £25m). Central costs in the year are expected to be c.£1.9m (FY22: £1.7m), higher than the prior year due to general inflationary pressures. The Board expects FY24 Group revenue and profitability to increase slightly over FY23 levels. 

 

Physiomics* 1.65p  £2.2m (PYC.L) 

The oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions announces the hiring this week of a new senior member of its team, Dr Venkata Putcha, as Head of Biostatistics. Dr Putcha brings with him over 22 years of experience working within drug development, with over 17 years working for many of the top-tier pharmaceutical and CRO companies. He has held a variety of senior biostatistics and programming roles across academia and industry, both working in-house and as an independent consultant. 

 

Renalytix AI 67p  £63.7m (RENX.L) 

The company that commercialises FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with type 2 diabetes and chronic kidney disease announces that the Centers for Medicare & Medicaid Services (CMS) has published the price for the Company's Food and Drug Administration (FDA) authorised kidneyintelX.dkd test on the nationwide Clinical Laboratory Fee Schedule at $950. This pricing will be effective as of January 1, 2024 and maintained for a minimum of three years. The Company believes the CMS action, which has included both expert and public review and comment, affirms the value of the KidneyIntelX testing platform. 

 

Sareum Holdings* 80p  £56.1m (SAR.L) 

A biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, will announce its audited financial results for the year ended 30 June 2023 on Monday, 9 October 2023. The Company will also be holding a live presentation to investors on Wednesday, 11 October 2023 at 10.00 am BST via the Investor Meet Company (IMC) platform. 

 

Tortilla Mexican Grill  66p £25.5m (MEX.L) 

The fast-casual Mexican restaurant business in the UK today announces its unaudited interim results for the 26 weeks ended 2 July 2023 (H1 FY23). Revenue growth of 22% was recorded of £32.7m (H1 FY22: £26.9m), however adjusted EBITDA declined to £1.8m (H1 FY22: £2.5m), whilst trading was in-line with market expected financial performance and noted that the prior year amount benefitted from £1.1m of Government support. The Company announced a loss before tax of £0.6m (H1 FY22: profit before tax £0.3m) and net debt of £1.6m at period end (H1 FY22 £3.2m net cash). The Group opened three new stores including their first store in Northern Ireland. The Company remain confident of being broadly in line with their targeted adjusted EBITDA for FY23. 

 

* A corporate client of Hybridan LLP

** Arranged by most recent first

*** Alphabetically arranged

 

Status of this Note and Disclaimer

This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II       Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii)  persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.